BEBT-109, A PAN-MUTANT-SELECTIVE EGFR INHIBITOR WITH POTENT ANTITUMOR ACTIVITY IN EGFR-MUTANT NON-SMALL CELL LUNG CANCER

BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer

EGFR mutation-positive NSCLC tumors are highly heterogeneous, therefore, exploring an agent simultaneously targeting multiple EGFR mutations may be valuable for clinical practice.Compared with osimertinib, BEBT-109 shows more sensitive and extensive antitumor activity in EGFR mutant NSCLC, while sparing wild-type EGFR cell lines.Meanwhile, unlike t

read more

Unusual localized gingival redness: a case report

Inflammation of the gingiva is one of the most common and routine findings in dental practice.These routine appearances of inflammatory gingivae can show peculiarity when associated with an underlying systemic condition or because of reactive, benign, or malignant pathologies.This case highlights minute clinical signs of the gingiva that deviate fr

read more


Recent Advances in the Therapeutic Efficacy of Artesunate

Artesunate, a semisynthetic artemisinin derivative, is well-known and used as the first-line drug for treating malaria.Apart from treating malaria, artesunate has also been found to have biological activity against a variety of cancers and viruses.It also exhibits antidiabetic, anti-inflammatory, anti-atherosclerosis, immunosuppressive activities,

read more